NEW YORK CITY (dpa-AFX) - Biohaven Pharmaceutical Holding Company Ltd. (BHVN) and Pfizer Inc. (PFE) reported positive top-line results from an Asia-Pacific, phase 3 clinical trial of rimegepant in adults for the acute treatment of migraine. The study met its co-primary endpoints of freedom from pain and freedom from most bothersome migraine-associated symptom including either nausea, phonophobia or photophobia at 2-hours following a single oral dose of rimegepant.
In the study, a single oral dose of rimegepant 75 mg provided significant relief of migraine symptoms and return to normal function at 2 hours and delivered sustained efficacy that lasted up to 48 hours for many patients. Rimegepant showed a favorable safety and tolerability profile, the company said.
Donnie McGrath, Executive Chairman of Biohaven's subsidiary in China, BioShin, said: 'The results from this study demonstrate the effectiveness of rimegepant and highlight the potential impact for patients in Asia Pacific, if approved.'
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2022 AFX News
